Orion Pharma's ODM-212 wins EU Orphan Designation for mesothelioma
Orion Pharma has secured European Commission Orphan Designation for ODM-212, its investigational oral pan-TEAD inhibitor, for the treatment of malignant mesothelioma. The designation follows a recommendation from the EMA's Committee for Orphan Medicinal Products and mirrors the Orphan Drug Designation the US Food and Drug Administration granted to the same compound for the same indication.
The dual-jurisdiction designation matters commercially. In the EU, Orion is now eligible for protocol assistance, reduced regulatory fees and, most significantly, a ten-year period of market exclusivity following any future approval. The European Commission is clear, however, that Orphan Designation does not accelerate development timelines or confer any advantage in the regulatory review itself.
The science and the trial
ODM-212 targets the Hippo signalling pathway, which governs cell growth and organ size. When the pathway is dysregulated, particularly through overactivation of the YAP and TAZ proteins, tumour growth can become uncontrolled and resistance to existing therapies can develop. ODM-212 disrupts this process through three mechanisms: blocking TEAD transcription factors, preventing YAP-TEAD protein-protein interactions, and inhibiting TEAD auto-palmitoylation, a post-translational modification that is necessary for TEAD function.
The compound is being evaluated in the Phase 2 TEADES study (NCT06725758), which is enrolling patients with malignant pleural mesothelioma, epithelioid hemangioendothelioma, and other solid tumours associated with Hippo pathway dysfunction. All participants will have exhausted standard treatment options. The trial is running at oncology centres in the US and Europe.
Praveen Aanur, Chief Medical Officer for the Oncology Therapy Area at Orion Pharma, said the designation "highlights the need for new treatments in mesothelioma and reinforces our commitment to developing innovative therapies for patients with rare cancers."
Market context and competitive landscape
Malignant pleural mesothelioma is closely linked to asbestos exposure and carries a poor prognosis, with a median survival typically measured in months from diagnosis. The approved treatment landscape is limited: platinum-based chemotherapy combinations and, more recently, the nivolumab plus ipilimumab regimen, which gained regulatory acceptance in the US and EU for unresectable disease. Beyond these options, there are few validated paths for patients who progress.
The Hippo pathway and TEAD inhibition represent a relatively nascent therapeutic target. A number of academic groups and smaller biotechs are exploring YAP/TAZ-TEAD interactions in parallel, and at least one other TEAD inhibitor has entered clinical evaluation. Orion's decision to pursue a pan-TEAD approach across multiple Hippo-dysregulated tumour types, rather than restricting the TEADES study to mesothelioma alone, could broaden the commercial opportunity if efficacy signals emerge across histologies.
Orion Pharma, a Finnish group with approximately EUR 1.89 billion in net sales in 2025 and around 4,000 employees, has oncology and pain as its two principal R&D focus areas. The company has proprietary products already on the market for cancer and neurological indications, giving it established regulatory and commercial infrastructure for oncology development. Investors and clinical observers will now look to TEADES for interim efficacy and safety data as the key near-term catalyst for ODM-212.